INDEMNIFICATION AGREEMENTIndemnification Agreement • October 6th, 2017 • Spero Therapeutics, Inc. • Pharmaceutical preparations • Delaware
THIS INDEMNIFICATION AGREEMENT (“Agreement”) is made as of [●], 2017 by and between SPERO THERAPEUTICS, INC., a Delaware corporation (the “Company”), and [●] (the “Indemnitee”). This Agreement supersedes and replaces any and all previous Agreements between the Company and Indemnitee covering the subject matter of this Agreement.
LEASE AGREEMENT by and between U.S. REIF CENTRAL PLAZA MASSACHUSETTS, LLC as Landlord and SPERO OPCO INC. as Tenant With respect to the property known as 675 Massachusetts Avenue, Cambridge, Massachusetts Dated as ofLease Agreement • October 6th, 2017 • Spero Therapeutics, Inc. • Pharmaceutical preparations • Massachusetts
THIS LEASE AGREEMENT (the “Lease”) is made and entered into as of this 24th day of August, 2015, by and between U.S. REIF CENTRAL PLAZA MASSACHUSETTS, LLC, a Delaware limited liability company (the “Landlord”), and SPERO OPCO INC., a Delaware corporation (the “Tenant”).
Spero OpCo, Inc. Cambridge, MA 02139Spero Therapeutics, Inc. • October 6th, 2017 • Pharmaceutical preparations
The purpose of this letter agreement (the “Agreement”) is to confirm the terms regarding your separation of employment with Spero OpCo, Inc. (the “Company”) as set forth herein and in that certain employment agreement dated June 24, 2015 (the “Employment Agreement”) between you and the Company. You understand and agree that wherever the term “Company” is used in this Agreement it shall refer to Company, its divisions, parent, affiliates, subsidiaries and related entities, and its and their respective officers, directors, employees, agents, representatives, successors and assigns. As more fully set forth below, Company desires to provide you with severance pay as outlined in the Employment Agreement in exchange for certain agreements by you.
RESTRICTED STOCK AGREEMENT SPERO THERAPEUTICS, INC.Restricted Stock Agreement • October 6th, 2017 • Spero Therapeutics, Inc. • Pharmaceutical preparations • Delaware
AGREEMENT made as of the [ ] day of [ ], 2017 (the “Grant Date”), between Spero Therapeutics, Inc. (the “Company”), a Delaware corporation, and [ ] (the “Participant”).
SPERO THERAPEUTICS, INC. INVESTORS’ RIGHTS AGREEMENT JUNE 30, 2017Investors’ Rights Agreement • October 6th, 2017 • Spero Therapeutics, Inc. • Pharmaceutical preparations • Delaware
THIS INVESTORS’ RIGHTS AGREEMENT (this “Agreement”) is made as of the 30th day of June, 2017, by and among Spero Therapeutics, Inc., a Delaware corporation (the “Company”), and each of the investors listed on Schedule A hereto, each of which is referred to in this Agreement as an “Investor”, and each of the stockholders listed on Schedule B hereto, each of whom is referred to herein as a “Key Holder.”
AMENDED AND RESTATED LICENSE AGREEMENTLicense Agreement • October 6th, 2017 • Spero Therapeutics, Inc. • Pharmaceutical preparations • New York
This Amended and Restated License Agreement (this “Agreement”), dated as of June 28, 2017 (the “Effective Date”), is made by and between Northern Antibiotics Oy (Ltd.), a corporation organized under the laws of Finland (“Northern”), and Spero Potentiator, Inc., a Delaware corporation (“Spero”). Northern and Spero are sometimes hereinafter referred to each as a “Party” and collectively as the “Parties.”
SUBLEASESublease • October 6th, 2017 • Spero Therapeutics, Inc. • Pharmaceutical preparations • Massachusetts
This SUBLEASE (“Sublease”) is made as of July 6, 2016 (the “Effective Date”), by and between Tetraphase Pharmaceuticals, Inc., a Delaware corporation having a place of business at 480 Arsenal Street, Watertown, MA 02472 (“Sublessor”) and SperoOpCo, Inc., a Delaware corporation (“Sublessee”).
CONFIDENTIAL TREATMENT REQUESTED LICENSE AGREEMENT BY AND BETWEEN MEIJI SEIKA PHARMA CO., LTD. AND SPERO OPCO, INC. Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange...Confidential Treatment Requested • October 6th, 2017 • Spero Therapeutics, Inc. • Pharmaceutical preparations • New York
This License Agreement (this “Agreement”) is made and effective as of the 14th day of June, 2017 (the “Effective Date”) by and between Meiji Seika Pharma Co., Ltd., a Japanese corporation with offices at 2-4-16, Kyobashi, Chuo-ku, Tokyo, 104-8002 Japan (“Meiji”) and Spero OpCo, Inc., a Delaware corporation with offices at 675 Massachusetts Avenue, 14th Floor, Cambridge, MA 20139, USA (“Spero”).
